A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
NCT 06384352 Brief Summary This is a multicenter, open-label, Phase 1 study.…
Read more arrow_forwardNCT 06384352 Brief Summary This is a multicenter, open-label, Phase 1 study.…
Read more arrow_forwardInside Rare is a monthly newsletter that shares the latest news, events and stories connecting the rare community.